Zacks Research Upgrades Lisata Therapeutics (NASDAQ:LSTA) to “Hold”

Lisata Therapeutics (NASDAQ:LSTA) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Several other equities analysts have also recently issued reports on LSTA. cut shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Tuesday, April 21st. Finally, HC Wainwright cut shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Lisata Therapeutics has an average rating of “Reduce” and a consensus price target of $15.00.

Lisata Therapeutics Stock Performance

Shares of LSTA stock opened at $3.12 on Monday. Lisata Therapeutics has a one year low of $1.81 and a one year high of $5.07. The company’s 50-day moving average is $4.19 and its 200 day moving average is $3.37. The company has a market capitalization of $28.42 million, a price-to-earnings ratio of -1.68 and a beta of 0.81.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.50) EPS for the quarter. As a group, research analysts predict that Lisata Therapeutics will post -1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

Institutional investors have recently made changes to their positions in the business. Cerity Partners LLC bought a new position in shares of Lisata Therapeutics in the 2nd quarter worth approximately $32,000. CIBC Bancorp USA Inc. purchased a new stake in Lisata Therapeutics in the 3rd quarter worth approximately $37,000. SOL Capital Management CO purchased a new stake in Lisata Therapeutics in the 1st quarter worth approximately $61,000. Ground Swell Capital LLC purchased a new stake in Lisata Therapeutics in the 3rd quarter worth approximately $62,000. Finally, Renaissance Technologies LLC increased its holdings in Lisata Therapeutics by 6.1% in the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after acquiring an additional 7,093 shares in the last quarter. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.